TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1590705

Group type: EXPERIMENTAL
Intervention: Ofloxacin for 5 days
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ofloxacin for 3 days
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ofloxacin for 5 days (shigellosis)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ofloxacin for 3 days (all cases)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ofloxacin for 3 days (enterotoxigenic E. coli)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ofloxacin for 3 days (shigellosis)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ofloxacin for 3 days (bacterial enteropathogen)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ofloxacin for 3 days (numerous leukocytes in stool)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 232
Study: 3703176

Group type: EXPERIMENTAL
Intervention: PK 8165 (50, 100, 150 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control session (no treatment)
Number of subjects: 8
Study: 29926988

Group type: EXPERIMENTAL
Intervention: Galantamine 8 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28069279

Group type: EXPERIMENTAL
Intervention: Masitinib (6 mg/kg per day over 24 weeks)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 26308758

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (20 mg of omeprazole, 1g of amoxicillin, 500 mg of metronidazole, and 400 mg of bismuth compound for 7 days)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Pylorex Plus (500 mg for 15 days)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Pylorex Plus
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 210
Study: 23147078

Group type: EXPERIMENTAL
Intervention: Customized birth weight percentiles (LGAcust)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Population birth weight percentiles (LGApop)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Customized and population norms
Number of subjects: 491
Study: 20577116

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hydroxypropyl methyl cellulose (control)
Number of subjects: 22
Study: 18713259

Group type: EXPERIMENTAL
Intervention: Adjunctive antimicrobial photodynamic therapy (aPDT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (scaling and root planing only)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (with and without adjunctive aPDT)
Number of subjects: 20
Study: 16365181

Group type: EXPERIMENTAL
Intervention: Chemotherapy in CALGB studies for extensive-stage small-cell lung cancer
Number of subjects: 995
Study: 12941995

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination therapy regimen 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed-dose combination therapy regimen 2
Number of subjects: 0
Study: 11055467

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 6614

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 6614

Group type: COMPARATOR
Intervention: Conventional treatment (beta-blockers and diuretics)
Number of subjects: 6614
Study: 9484109

Group type: EXPERIMENTAL
Intervention: Lactitol (4-O (beta-galactosyl)-D-glucitol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sucrose (control)
Number of subjects: 12
Study: 7831429

Group type: EXPERIMENTAL
Intervention: Yohimbine (0.4 mg/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 7
Study: 3523740

Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg/day
Number of subjects: 18
Study: 31630249

Group type: EXPERIMENTAL
Intervention: Intra-esophageal injection of 10 mL of thickened water at 10 mL/s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intra-esophageal injection of 3 mL of thickened water at 10 mL/s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intra-esophageal injection in the upper region
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Voluntary swallowing in the upper esophageal region
Number of subjects: 10
Study: 31201136

Group type: EXPERIMENTAL
Intervention: Revascularisation (bypass or angioplasty)
Number of subjects: 452
Study: 27988356

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 2972

Group type: COMPARATOR
Intervention: White race
Number of subjects: 2972
Study: 26651478

Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioural therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Face-to-face cognitive behavioural therapy
Number of subjects: 156
Study: 23458040

Group type: EXPERIMENTAL
Intervention: Identification of recurrent laryngeal nerve during surgery (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No identification of recurrent laryngeal nerve during surgery (Group B)
Number of subjects: 100
Study: 20981504

Group type: EXPERIMENTAL
Intervention: Prospective ECG gating
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retrospective ECG gating
Number of subjects: 60
Study: 20008244

Group type: EXPERIMENTAL
Intervention: Allogeneic donor transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive pediatric protocols
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched unrelated donors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal residual disease studies
Number of subjects: 0
Study: 17926617

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus behavior therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Behavior therapy
Number of subjects: 60
Study: 14693413

Group type: EXPERIMENTAL
Intervention: Acarbose (titrated to a maximum of 100mg three times daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tolbutamide (titrated to a maximum of 2000 mg in three doses)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 96
Study: 11204938

Group type: EXPERIMENTAL
Intervention: Novofem (1 mg estradiol + 1 mg norethisterone acetate)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Activelle (1 mg estradiol + 0.5 mg norethisterone acetate)
Number of subjects: 23
Study: 9603128

Group type: EXPERIMENTAL
Intervention: 6‐wk supervised, multimodality endurance exercise training program (EXT)
Number of subjects: 20
Study: 7530064

Group type: EXPERIMENTAL
Intervention: N,G‐nitro‐L‐arginine methyl ester (L‐NAME)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 6
Study: 3134898

Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31126277

Group type: EXPERIMENTAL
Intervention: Complex on-site intervention including physician visits, nursing staff involvement, computerized documentation system (CoCare Cockpit), joint trainings and audits, structured treatment paths, after-hours medical care availability.
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Care/treatment as usual (control group).
Number of subjects: 4000
Study: 28926793

Group type: EXPERIMENTAL
Intervention: CX157
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24918474

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with behavioral approach
Number of subjects: 216

Group type: COMPARATOR
Intervention: Prescription of Physical Activity (PPA)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise without behavioral approach
Number of subjects: 216
Study: 23743809

Group type: EXPERIMENTAL
Intervention: Active treatment with indapamide sustained release 1.5 mg +/- perindopril 2-4 mg
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 263
Study: 21649813

Group type: EXPERIMENTAL
Intervention: HA(E) (Emervel Deep)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HA(P) (Restylane Perlane)
Number of subjects: 0
Study: 18319586

Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 microg b.i.d., salmeterol 50 microg b.i.d. and oxitropium bromide 200 microg t.i.d.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo, salmeterol 50 microg b.i.d. and oxitropium bromide 200 microg t.i.d.
Number of subjects: 8
Study: 16507602

Group type: EXPERIMENTAL
Intervention: 41% leucine (41% Leu) EAA
Number of subjects: 4

Group type: COMPARATOR
Intervention: 26% leucine (26% Leu) EAA
Number of subjects: 4
Study: 12656812

Group type: EXPERIMENTAL
Intervention: Microabrasion alone every 2 weeks (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Microabrasion with 15% trichloroacetic acid (TCA) every 3 weeks (group 2)
Number of subjects: 20
Study: 10730285

Group type: EXPERIMENTAL
Intervention: Compoglass-F/Syntac SC with salivary contamination
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dyract-AP/Prime and Bond 2.1 with salivary contamination
Number of subjects: 16

Group type: COMPARATOR
Intervention: Compoglass-F/Syntac SC without salivary contamination
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dyract-AP/Prime and Bond 2.1 without salivary contamination
Number of subjects: 16
Study: 9186346

Group type: EXPERIMENTAL
Intervention: Computerized nuclear texture analysis
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Sialyl Lewis(x) molecules
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Routine clinical and laboratory data (sedimentation rate, alkaline phosphatase, hemoglobin)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Performance status, pain due to metastasis, extent of bone lesions
Number of subjects: 262
Study: 7903213

Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metoprolol 200 mg once daily
Number of subjects: 40
Study: 6741666

Group type: EXPERIMENTAL
Intervention: Supportive group therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Covert sensitization
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-specific control
Number of subjects: 28

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 28
Study: 31064260

Group type: EXPERIMENTAL
Intervention: Machine learning classification using LASSO approach
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Background data including teacher and caregiver ratings
Number of subjects: 483
Study: 29223479

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab with anthracycline-containing chemotherapy (FEC)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab with anthracycline-free chemotherapy (docetaxel)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Pertuzumab plus trastuzumab with docetaxel and carboplatin
Number of subjects: 223
Study: 27177615

Group type: EXPERIMENTAL
Intervention: Chlorella (5 g/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 22643187

Group type: EXPERIMENTAL
Intervention: Decompressive surgery with additional implantation of the Coflex interspinous device
Number of subjects: 62

Group type: COMPARATOR
Intervention: Decompressive surgery alone
Number of subjects: 62
Study: 21031523

Group type: EXPERIMENTAL
Intervention: 0.5 molar gadobenate dimeglumine
Number of subjects: 74

Group type: COMPARATOR
Intervention: 1.0 molar gadobutrol
Number of subjects: 74
Study: 16435071

Group type: EXPERIMENTAL
Intervention: Group 1 (well-informed about statins)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Group 2 (not well-informed about statins)
Number of subjects: 202
Study: 11465710

Group type: EXPERIMENTAL
Intervention: Diclofenac + Misoprostol (75 mg diclofenac + 200 microg misoprostol twice daily for 6 weeks)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Acetaminophen (1,000 mg acetaminophen 4 times daily for 6 weeks)
Number of subjects: 227
Study: 9711370

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 73

Group type: COMPARATOR
Intervention: Routine case management
Number of subjects: 73
Study: 7986543

Group type: EXPERIMENTAL
Intervention: Sonicated albumin with 50% dextrose (threefold dilution, sonicated for 80 to 100 seconds)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sonicated albumin with 50% dextrose (sevenfold dilution, sonicated for 80 to 100 seconds)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sonicated albumin (control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sonicated albumin with 50% dextrose (onefold dilution, sonicated for 40 seconds)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sonicated albumin with 50% dextrose (threefold dilution, sonicated for 40 seconds)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sonicated albumin with 50% dextrose (sevenfold dilution, sonicated for 40 seconds)
Number of subjects: 10
Study: 2543201

Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 178
Study: 4853634

Group type: EXPERIMENTAL
Intervention: Physical training (indoors, three sessions a week, individual training) for 3 months
Number of subjects: 63

Group type: COMPARATOR
Intervention: Reference group (29 patients)
Number of subjects: 63
Study: 31607603

Group type: COMPARATOR
Intervention: Standard-dose oral Rotarix vaccine
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: High-dose oral Rotarix vaccine
Number of subjects: 220
Study: 30076113

Group type: EXPERIMENTAL
Intervention: IV rt-PA treatment for patients with body weight >100 kg
Number of subjects: 105
Study: 26437613

Group type: EXPERIMENTAL
Intervention: Chamomile tea (3 g/150 mL hot water) 3 times per day immediately after meals for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Water regimen for 8 weeks
Number of subjects: 64
Study: 24700386

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 60
Study: 22587684

Group type: EXPERIMENTAL
Intervention: Telephone counselling
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Face-to-face counselling
Number of subjects: 625

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 625
Study: 20346304

Group type: EXPERIMENTAL
Intervention: Baseline heart rate (HR) >= 70 beats/min
Number of subjects: 9580

Group type: COMPARATOR
Intervention: Baseline heart rate (HR) < 70 beats/min
Number of subjects: 9580

Group type: EXPERIMENTAL
Intervention: Every 10-beats/min increase in HR at rest
Number of subjects: 9580

Group type: EXPERIMENTAL
Intervention: HR >= 70 beats/min
Number of subjects: 9580
Study: 19073842

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sodium Valproate
Number of subjects: 48
Study: 16416508

Group type: EXPERIMENTAL
Intervention: Parent-imposed restrictions on driving conditions
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Parent-imposed consequences for driving rule violations
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Female parents
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Male teens
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Discordance with restricted driving conditions
Number of subjects: 579
Study: 12885715

Group type: EXPERIMENTAL
Intervention: LCP-supplemented formula (LF)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control-formula (CF)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Breastfed (BF)
Number of subjects: 397
Study: 10095142

Group type: EXPERIMENTAL
Intervention: Human milk feeding
Number of subjects: 18
Study: 8971950

Group type: EXPERIMENTAL
Intervention: New lower-prime hollow-fibre membrane oxygenators with uncoated stainless steel heat exchangers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (other models of membrane oxygenators)
Number of subjects: 60
Study: 1987229

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Lesion stenosis 60% to 74%
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Lesion stenosis 75% to 89%
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Lesion stenosis 90% to 99%
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Lesion stenosis 100%
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Noncalcified lesions
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Calcified lesions
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Nonthrombotic lesions
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Thrombotic lesions
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Other vessels
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Right coronary artery lesions
Number of subjects: 826
Study: 6881497

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 15

Group type: COMPARATOR
Intervention: General anaesthetic
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 31190621

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0
Study: 29460884

Group type: EXPERIMENTAL
Intervention: Prolonged plaster of Contractubex
Number of subjects: 109

Group type: COMPARATOR
Intervention: Dynamic observation (Control)
Number of subjects: 109
Study: 27587419

Group type: EXPERIMENTAL
Intervention: Silver-impregnated dressings
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard dressings
Number of subjects: 117
Study: 24508468

Group type: EXPERIMENTAL
Intervention: COPA model (integrated primary care with intensive case management)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 428
Study: 21423055

Group type: EXPERIMENTAL
Intervention: n‐3FA supplements (stopped an average of 2.3 days before surgery)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no n‐3FA supplements)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: n‐3FA supplements
Number of subjects: 95
Study: 20946445

Group type: EXPERIMENTAL
Intervention: Telephone advice (n=235) in addition to usual care
Number of subjects: 468

Group type: COMPARATOR
Intervention: Usual care only (n=233)
Number of subjects: 468
Study: 16971011

Group type: EXPERIMENTAL
Intervention: Beta‐brachytherapy (Beta‐Cath)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Paclitaxel‐eluting stent implantation (Taxus‐Express2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Stent implantation (Taxus‐Express2)
Number of subjects: 37
Study: 15747149

Group type: EXPERIMENTAL
Intervention: 3D ultrasound (3D US)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2D ultrasound (2D US)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of 2D and 3D ultrasound
Number of subjects: 60
Study: 12174841

Group type: EXPERIMENTAL
Intervention: Erbium:yttrium-aluminum-garnet laser with energy level of 250 mJ at 103 pulses per second
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erbium:yttrium-aluminum-garnet laser with energy level of 80 mJ at 166 pulses per second
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erbium:yttrium-aluminum-garnet laser with energy level of 80 mJ at 166 pulses per second with concomitant water irrigation
Number of subjects: 0
Study: 10467204

Group type: EXPERIMENTAL
Intervention: Continuous ST monitoring
Number of subjects: 206
Study: 8684301

Group type: EXPERIMENTAL
Intervention: Non-occupational (domestic and environmental) exposure to asbestos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to MMMF and other agents
Number of subjects: 0
Study: 1977731

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 361068

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg twice daily) for 4 to 17 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (one tablet twice daily) for 4 to 12 weeks
Number of subjects: 33
Study: 31390590

Group type: EXPERIMENTAL
Intervention: TES program (screening and stepped care)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 349
Study: 28478317

Group type: EXPERIMENTAL
Intervention: Vacuum sealing drainage (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment (group B)
Number of subjects: 80
Study: 25311059

Group type: EXPERIMENTAL
Intervention: High nut consumption (≥1 time/day)
Number of subjects: 9660
Study: 24280469

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Spinal Orthopedic Manipulation (TCSOM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pinaverium Bromide Dicetel (PBD)
Number of subjects: 60
Study: 21676131

Group type: EXPERIMENTAL
Intervention: Affective Story Task
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study: 20214051

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%/dorzolamide 20%/brimonidine 0.2%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol 0.5%/dorzolamide 2%
Number of subjects: 0
Study: 16960270

Group type: EXPERIMENTAL
Intervention: 10 cm H2O of CPAP during cardiopulmonary bypass (Group I; n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (Group II; n = 60) where the patient's lungs were vented to atmosphere during the bypass period
Number of subjects: 120
Study: 15074084

Group type: EXPERIMENTAL
Intervention: Yangxue Qingnao granule (YXQN) plus conventional medical treatment
Number of subjects: 167

Group type: COMPARATOR
Intervention: Conventional medical treatment alone
Number of subjects: 167
Study: 11140187

Group type: EXPERIMENTAL
Intervention: Training to shift attention between acoustic cues; feedback based on category-level identification; duration not specified.
Number of subjects: 0